Linguistic Validation of the Inflammatory Bowel Disease Questionnaire-Short Form (IBDQ-9) in Iranian Population

Document Type : Original Article (s)

Authors

1 Researcher, Medical Students Research Center, Isfahan University of Medical Sciences and Poursina Hakim Research Institute, Isfahan

2 Researcher, Medical Students Research Center, Isfahan University of Medical Sciences and Poursina Hakim Research Institute, Isfahan,

3 Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan,

4 Associate Professor, Department of Gastroenterology, Isfahan University of Medical Sciences and Poursina Hakim Research Institute, Isfahan,

Abstract

Background: Quality of life is significantly reduced in patients with inflammatory bowel disease (IBD). As there was no specific instrument for assessment of quality of life of Iranian IBD patients, we aimed to linguistically validate the Inflammatory Bowel Disease Questionnaire-Short Form (IBDQ-9) in Iranian IBD patients.Methods: The IBDQ-9 was translated into Persian and culturally adapted following the standard forward-backward translation method. A sample of 100 IBD patients (50 Ulcerative Colitis and 50 Crohn’s Disease) completed the IBDQ-9, Short-Form-36 Health Survey (SF-36), Simplified Crohn’s Disease Activity Index (SCDAI), Simple Clinical Colitis Activity Index (SCCAI), and Hospital Anxiety and Depression Scale (HADS). Internal consistency was assessed using Cronbach’s alpha coefficient. To analyze the construct and discriminant validities, the IBDQ-9 and its subscales were correlated to SF-36 total and subscale scores and disease activity indices and HADS score, respectively.Finding: The Cronbachs’ alpha coefficient of the IBDQ-9 was 0.76. There was significant correlations of the IBDQ-9 score with SF-36 total (r = 0.524, P < 0.001) and subscale scores (r = 0.476 to 0.541, P < 0.001). Also there was significant correlations of the IBDQ-9 score with SCDAI (r = -0.424, p = 0.025), SCCAI (r = -0.530, P < 0.001), and depression (r = -0.417, P < 0.001) and anxiety (r = -0.362, P < 0.001) scores.Conclusion: The Persian version of the IBDQ-9 appears to be an appropriate instrument to assess quality of life of Iranian IBD patients. Further validation studies are warranted to investigate the reliability and validity of the IBDQ-9 after more editionslly.

Keywords

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 417-29.
  2. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol 2005; 20(11): 1691-5.
  3. Pizzi LT, Weston CM, Goldfarb NI, Moretti D, Cobb N, Howell JB, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12(1): 47-52.
  4. Irvine EJ. Is disease-specific health-related quality of life measurement a necessary evil when assessing clinical outcomes in inflammatory bowel disease? Dig Liver Dis 2000; 32(8): 689-90.
  5. Fayers PM, Machin D. Quality of Life: The assessment, analysis and interpretation of pa-tient-reported outcomes. 2nd ed. New York: John Wiley & Sons; 2007.
  6. Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1995; 1(2):117-34.
  7. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research 2005; 14: 875-82.
  8. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106(2): 287-96.
  9. Verissimo R. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J Gastrointestin Liver Dis 2008; 17(4): 439-44.
  10. Irvine EJ. The Short Inflammatory Bowel Dis-ease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. 1996.
  11. Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99(3): 457-61.
  12. Elliott PR, Lennard-Jones JE, Hathway N. Sim-ple index of Crohn's disease activity. Lancet 1980; 1(8173): 876.
  13. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43(1): 29-32.
  14. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8(2): 94-104.
  15. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130(5): 1538-51.
  16. Bijkerk CJ. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. 2003.
Journal of Isfahan Medical School
Volume 28, Issue 123 - Serial Number 123
November and December 2011
Pages 1850-1859

Files

History

  • Receive Date: 25 January 2011
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics